BackResmed Overview
Resmed Inc.

Resmed Target Price

Analysts' average 12-month price target for Resmed is $250.

Get informed when a big investor buys or sells

+ Follow

Share Price

$219.98

Average Target Price

$246.5812.1% upside

12 analysts in the last 4 months

High: $300 | Low: $213

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Robert W. Baird$2133.2% downsideOpen
2026-08-07KeyBanc$25515.9% upsideOpen
2026-07-21UBSDavid Low$30036.4% upsideOpen
2026-07-16RBC Capital$2346.4% upsideOpen
2026-07-15Mizuho Securities$2200% upsideOpen
2026-07-10Jefferies$2252.3% upsideOpen
2026-07-08RBC Capital$27625.5% upsideOpen
2026-07-08Wells Fargo$2252.3% upsideOpen
2026-06-22KeyBanc$26620.9% upsideOpen
2026-06-17Morgan StanleyDavid Bailey$2304.6% upsideOpen
2026-05-01Robert W. Baird$2252.3% upsideOpen
2026-04-27KeyBanc$29031.8% upsideOpen
2026-04-13Evercore ISIAnthony Petrone$25515.9% upsideOpen
2026-01-30RBC CapitalCraig Wong-Pan$31442.7% upsideOpen
2026-01-30Stifel Nicolaus$26520.5% upsideOpen
2026-01-30KeyBancBrett Fishbin$30237.3% upsideOpen
2026-01-30Robert W. Baird$28127.7% upsideOpen
2026-01-30Piper Sandler$27525% upsideOpen
2025-12-18Stifel NicolausJonathan Block$26018.2% upsideOpen
2025-12-16Robert W. Baird$27525% upsideOpen
2025-12-12UBSMarcus Curley$34556.8% upsideOpen
2025-11-03Robert W. Baird$30036.4% upsideOpen
2025-10-31KeyBancBrett Fishbin$29935.9% upsideOpen
2025-10-31Morgan StanleyDavid Bailey$30538.6% upsideOpen
2025-10-21Morgan Stanley$30438.2% upsideOpen
2025-10-13Wells Fargo$28027.3% upsideOpen
2025-05-20Morgan StanleyDavid Bailey$28630% upsideOpen
2025-04-24KeyBancBrett Fishbin$27424.6% upsideOpen
2025-04-16Mizuho SecuritiesAnthony Petrone$26520.5% upsideOpen
2025-03-05Stifel Nicolaus$2409.1% upsideOpen
2025-01-31Piper SandlerAdam Maeder$26018.2% upsideOpen
2024-12-12Stifel NicolausJonathan Block$25013.6% upsideOpen
2024-10-01RBC CapitalCraig Wong-Pan$2241.8% upsideOpen
2024-09-23Robert W. BairdJoe Vruwink$28027.3% upsideOpen
2024-09-18Wolfe ResearchMike Polark$18018.2% downsideOpen
2024-04-10RBC CapitalCraig Wong-Pan$18715% downsideOpen
2024-04-01Stifel NicolausMike Matson$2241.8% upsideOpen
2023-10-27OppenheimerSuraj Kalia$17520.4% downsideOpen
2023-09-06NeedhamMike Matson$18018.2% downsideOpen
2022-06-20RBC CapitalCraig Wong-Pan$24410.9% upsideOpen
2022-04-29RBC Capital$2335.9% upsideOpen
2021-10-14OppenheimerSuraj Kalia$31241.8% upsideOpen
2021-08-04Morgan StanleySean Laaman$25013.6% upsideOpen
2021-07-28JefferiesAnthony Petrone$2409.1% upsideOpen

Resmed (RMD) FAQ

Resmed's target price stands at $250. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $250 for RMD implies 12.1% upside versus today's price ($219.98). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Resmed's target price evolved across reporting periods, while the comparison chart places RMD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Resmed's reading of $250 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.